PD-1/CTLA-4 Combination Drives Progress Across Tumor Types
Investigators of an ongoing phase 1a/1b multicohort trial are studying whether addition of adaptive immune activators increases the benefit derived from anti–PD-1 antibodies in multiple tumor types.
United States Danafarber Cancer Institute Brunob Bockorny Benjaminl Schlechter Harvard Medical School Society For Immunotherapy Of Cancer
Source: onclive.com